HK1197028A1 - 芳香族陽離子肽及其用途 - Google Patents

芳香族陽離子肽及其用途

Info

Publication number
HK1197028A1
HK1197028A1 HK14110477A HK14110477A HK1197028A1 HK 1197028 A1 HK1197028 A1 HK 1197028A1 HK 14110477 A HK14110477 A HK 14110477A HK 14110477 A HK14110477 A HK 14110477A HK 1197028 A1 HK1197028 A1 HK 1197028A1
Authority
HK
Hong Kong
Prior art keywords
aromatic
same
cationic peptides
peptides
cationic
Prior art date
Application number
HK14110477A
Other languages
English (en)
Inventor
Wilson D Travis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197028A1 publication Critical patent/HK1197028A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
HK14110477A 2011-06-14 2014-10-21 芳香族陽離子肽及其用途 HK1197028A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496994P 2011-06-14 2011-06-14
US201161505479P 2011-07-07 2011-07-07
PCT/US2012/042261 WO2012174117A2 (en) 2011-06-14 2012-06-13 Aromatic-cationic peptides and uses of same

Publications (1)

Publication Number Publication Date
HK1197028A1 true HK1197028A1 (zh) 2015-01-02

Family

ID=47357702

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110477A HK1197028A1 (zh) 2011-06-14 2014-10-21 芳香族陽離子肽及其用途

Country Status (8)

Country Link
US (1) US20150118315A1 (zh)
EP (1) EP2720704A4 (zh)
JP (1) JP2014518213A (zh)
CN (2) CN105126071A (zh)
AU (1) AU2012271691A1 (zh)
CA (1) CA2839408A1 (zh)
HK (1) HK1197028A1 (zh)
WO (1) WO2012174117A2 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
ES2774962T3 (es) * 2013-03-05 2020-07-23 Enteris Biopharma Inc Productos farmacéuticos de administración oral
SG11201507226YA (en) 2013-03-15 2015-10-29 Protagonist Therapeutics Inc Hepcidin analogues and uses therof
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
WO2015048647A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
JP6626446B2 (ja) * 2013-12-27 2019-12-25 ステルス バイオセラピューティックス コープ 薬学的に適切な芳香族カチオン性ペプチド
US10053490B2 (en) 2014-01-22 2018-08-21 Agency For Science, Technology And Research Antimicrobial peptidomimetics
CN106459169A (zh) * 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
SG11201609614QA (en) 2014-05-16 2016-12-29 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
US10125164B2 (en) 2014-06-25 2018-11-13 Flamma S.P.A. Process for preparing D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
SI3160985T1 (sl) 2014-06-30 2021-11-30 Flamma S.P.A. Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
BR112017001010A2 (pt) 2014-07-17 2017-11-14 Protagonist Therapeutics Inc inibidores peptídicos orais do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias intestinais
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
KR102294577B1 (ko) * 2015-01-12 2021-08-26 엔터리스 바이오파마, 인크. 고체 경구 제형
CN113831392A (zh) 2015-03-06 2021-12-24 康德生物医疗技术公司 制备药物相关肽的方法
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
EP4092038A1 (en) * 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2019271812A1 (en) * 2018-05-16 2021-01-07 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition of KOR receptor agonist
BR112022000328A2 (pt) 2019-07-10 2022-03-15 Protagonist Therapeutics Inc Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
US11939361B2 (en) 2020-11-20 2024-03-26 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of Interleukin-23 receptor
WO2023063376A1 (ja) * 2021-10-13 2023-04-20 中外製薬株式会社 ペプチド化合物及び界面活性剤を含む組成物
WO2023214509A1 (ja) * 2022-05-02 2023-11-09 中外製薬株式会社 界面活性剤と併用するためのペプチド化合物を含む組成物
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
PL2604285T3 (pl) * 2003-05-01 2015-02-27 Cornell Res Foundation Inc Sposób i kompleksy nośnikowe do dostarczania cząsteczek do komórek
RU2376028C2 (ru) * 2004-01-23 2009-12-20 Корнелл Рисеч Фаундейшн, Инк. Способ уменьшения окислительного повреждения (варианты)
US20050282756A1 (en) * 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products

Also Published As

Publication number Publication date
EP2720704A4 (en) 2015-06-10
CN105126071A (zh) 2015-12-09
EP2720704A2 (en) 2014-04-23
WO2012174117A2 (en) 2012-12-20
WO2012174117A3 (en) 2013-03-28
AU2012271691A1 (en) 2014-01-16
CN103764159A (zh) 2014-04-30
CA2839408A1 (en) 2012-12-20
US20150118315A1 (en) 2015-04-30
JP2014518213A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
HK1223550A1 (zh) 芳香族陽離子肽及其用途
HK1244540A1 (zh) 芳香族陽離子肽及其用途
HK1197028A1 (zh) 芳香族陽離子肽及其用途
HK1208686A1 (zh) 芳香族陽離子肽及其用途
HK1249406A1 (zh) 芳族陽離子肽和使用它們的方法
IL260045B (en) Polypeptide structures and their uses
HK1201443A1 (zh) 芳香族陽離子肽及其用途
HK1199892A1 (zh) 經修飾的微型鐵調素肽及其使用方法
EP2566880A4 (en) AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
IL230918A0 (en) Modified proteins and peptides
HK1204772A1 (zh) 芳香族陽離子肽及其用途
EP2740741A4 (en) PEPTIDE OBTAINED FROM THE WNT FAMILY AND USES THEREOF
EP2721061A4 (en) STABILIZED VARIANT MAML PEPTIDES AND USES THEREOF
IL222027A (en) Peptides and their use
EP2782589A4 (en) ANTIMICROBIAL PEPTIDES AND METHOD FOR THEIR USE
EP2738255A4 (en) PEPTIDE FROM ERAP1 AND ITS USE
HK1203161A1 (zh) 肽和使用該肽的方法
EP2593595A4 (en) NOVEL PEPTIDES AND USES THEREOF
EP2793921A4 (en) PEPTIDES DERIVED FROM SAPOSIN A AND USES THEREOF
EP2742153A4 (en) PROTEIN AND PEPTIDE LIBRARIES
PL2627668T3 (pl) Peptydy i ich zastosowanie
EP2740740A4 (en) PEPTIDE DERIVED FROM A LIGAND EDAR AND USES THEREOF
HK1206977A1 (zh) 芳香族陽離子肽及其用途
EP2762149A4 (en) PEPTIDE DERIVED FROM ERYTHROPOIETIN AND USE THEREOF
GB201121236D0 (en) Proteins and peptides